Lilly diabetes drug rejected by FDA over manufacturing issue
The Lilly-Boehringer drug empagliflozin is projected to reach sales of $295 million for Lilly in 2019, but it won’t be able to sell it until issues are resolved at a German plant.
Health Care Businesses
Articles
Kentucky’s largest health system makes major jobs cut
Hospital company KentuckyOne Health, which employs more than 14,000 people in Kentucky and southern Indiana, says it has laid off about 500 people.
Lilly diabetes drug matches competitors’ effectiveness
The Indianapolis drugmaker said dulaglutide performed as well as Victoza, a best-selling drug for Type 2 diabetics made by Denmark-based Novo Nordisk. Analysts think dulaglutide could reach annual sales of $1.5 billion.
Lilly acquires animal health business, lowers forecast
Eli Lilly and Co. is buying a privately held, poultry-vaccine maker based in Germany to strengthen its Elanco animal health subsidiary.
Lilly drug shows promise as lung cancer treatment
Shares of Eli Lilly and Co. rose as much as 3.8 percent Wednesday morning after the Indianapolis-based drugmaker revealed that an experimental drug boosted overall survival among lung cancer patients in a large trial.
Deals up, dollars down in 2013 for Indiana life sciences firms
Venture capitalists and angel investors put a combined $31.9 million into 18 life sciences companies last year, with some of the largest amounts going to Nextremity Solutions, hc1.com and FAST BioMedical.
Falling reimbursements force Roche to innovate
U.S. sales are plunging for Roche Diagnostics Corp. and its fellow makers of diabetes-care devices because of lower reimbursements from the federal Medicare program. In five years, two of the four largest companies will have sold or closed their diabetes businesses, according to two industry analysts.
Analysts say health care law means fewer on job
Several million American workers will cut back their hours on the job or leave the nation's workforce entirely because of President Barack Obama's health care overhaul, congressional analysts said Tuesday.
U.S. venture gathers drugmakers to take on major diseases
Eli Lilly and Co., Pfizer Inc. and eight other large drugmakers will partner with the U.S. government in a $230 million effort to identify new approaches to treat Alzheimer’s, diabetes, lupus and arthritis.
Testosterone drugs under FDA review for heart-attack risk
Testosterone drugs, which make up a growing market for pharmaceutical companies such as Eli Lilly, are getting a closer look from U.S. regulators.
Rival’s lawsuit could delay launch of new Lilly insulin
Paris-based Sanofi sued Eli Lilly and Co. on Thursday for patent infringement. That suit triggers an automatic 30-month delay on Lilly’s plans to launch a similar version of Sanofi’s once-a-day insulin Lantus.
Indianapolis businessman indicted for health care fraud
Ronald Reed, the owner of Benchmark Mobility Corp., allegedly billed the Medicaid and Medicare programs for used wheelchairs, scooters and lift chairs as if they were brand new, obtaining nearly $443,000 in fraudulent sales.
Lilly said to be willing to pay $3.7B for biotech firm
A newspaper says Eli Lilly and Co. is a leading contender to acquire a Massachusetts-based biotech company with a troubled leukemia drug.
Hospital uncertainty prompts 350 job cuts at Hill-Rom
Hill-Rom Holdings Inc. will eliminate about 350 jobs over the next two years as a cost-saving move after the maker of hospital equipment saw its profit grow slower than expected.
Lilly reacquires migraine medicine after encouraging results
Positive results from a Phase 2 trial in patients convinced Lilly to reacquire an experimental migraine medicine. Lilly recorded a charge of $57 million to reflect the purchase price and the costs of further development.
Lilly forecasts sales, profit drop in face of rival generic drugs
In a warning shot to investors, the pharmaceutical giant says it expects “2014 to be the most financially challenging year of Lilly’s current period of patent expirations.”
Contract between UnitedHealthcare, IU Health to expire
IU Health has decided to still give patients the same “in network” co-pays and deductibles that UnitedHealthcare had negotiated under the expiring contracts, keeping patients’ costs the same until a new deal is reached.
Lilly, other drugmakers to keep paying doctors
Eli Lilly and Co., Pfizer Inc., Sanofi and other large drugmakers will keep paying doctors to give talks about their products, leaving GlaxoSmithKline Plc alone for now in its decision to halt such compensation.
Lilly foe still testing Alzheimer’s theory where others failed
Since 1998, there have been more than 100 attempts to develop an Alzheimer’s treatment, and all have failed. Such a product may generate as much as $5 billion annually for Merck, according to analysts
FDA approves first generic versions of Lilly’s Cymbalta
Cymbalta is Eli Lilly and Co. Inc.'s best-selling drug and posted 2012 sales of $4.7 billion, making it the fifth-highest selling medication in the world. The drug's patent expired Wednesday.